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Well-being, problematic alcohol 
consumption and acute subjective 
drug effects in past-year ayahuasca 
users: a large, international, self-
selecting online survey
Will Lawn1,2, Jaime E. Hallak3, Jose A. Crippa3, Rafael Dos Santos3, Lilla Porffy1, Monica J. 
Barratt5,6,7, Jason A. Ferris  4, Adam R. Winstock8 & Celia J. A. Morgan1,2
Ayahuasca is a natural psychedelic brew, which contains dimethyltryptamine (DMT). Its potential 
as a psychiatric medicine has recently been demonstrated and its non-medical use around the world 
appears to be growing. We aimed to investigate well-being and problematic alcohol use in ayahuasca 
users, and ayahuasca’s subjective effects. An online, self-selecting, global survey examining patterns of 
drug use was conducted in 2015 and 2016 (n = 96,901). Questions were asked about: use of ayahuasca, 
lysergic acid diethylamide (LSD) and magic mushrooms; demographics, current well-being and past-
year problematic alcohol use of past-year ayahuasca users and comparison drug users; and subjective 
effects of ayahuasca and comparison drugs. Ayahuasca users (n = 527) reported greater well-being than 
both classic psychedelic users (n = 18,138) and non-psychedelic drug-using respondents (n = 78,236). 
Ayahuasca users reported less problematic drinking than classic psychedelic users, although both 
groups reported greater problematic drinking than the other respondents. Ayahuasca’s acute subjective 
effects usually lasted for six hours and were most strongly felt one hour after consumption. Within our 
online, self-selecting survey, ayahuasca users reported better well-being than comparison groups and 
less problematic drinking than classic psychedelic users. Future longitudinal studies of international 
samples and randomised controlled trials are needed to dissect the effects of ayahuasca on these 
outcomes.
Ayahuasca (‘the vine of the soul’) is a powerfully psychoactive brew which is thought to have been used for several 
hundred years by indigenous people in the Amazon1. It is usually prepared by boiling the leaves of the Psychotria 
viridis bush, which contains N,N-dimethyltryptamine (DMT), and combining with the stems of the Banisteriopsis 
caapi vine, which contains the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine, to create a 
thick brown liquid2. DMT is a tryptamine hallucinogen which is thought to act primarily at 5-HT2A receptors but 
also at 5-HT2C and 5-HT1A3. DMT is orally inactive due to its breakdown by monoamine oxidase activity in the 
gastrointestinal tract. The β-carboline alkaloids in the Banisteriopsis caapi vine are monoamine oxidase inhibitors 
(MAO-I) and therefore render orally administered DMT psychoactive4.
Ayahuasca is used by both indigenous tribes and by members of modern syncretic religious groups in and 
around the Amazon, including the Santo Daime and Uniao do Vegetal2. However, use is not confined to the 
Amazon, and there has been suggestion of a recent global increase in use of the drug5, particularly amongst 
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tourists travelling to South America. Use is also suggested to have increased in Europe and the US amongst 
Western ‘neoShamans’6. The psychedelic state induced by ayahuasca often makes users reflect on personal con-
cerns and memories7 and produces intense emotions8. These effects are highly valued by ayahuasca users who 
characterize the drug experience as similar to a psychotherapeutic intervention7. Emerging scientific evidence 
complements the users’ view of ayahuasca as therapeutic: a small, uncontrolled pilot study found that symptoms 
of depression reduced following consumption of the brew9. There is further suggestion of its use in the treatment 
of addiction10–12.
If the drug is to represent an important treatment, however, it is critical that its short and long-term effects 
are investigated and safety well established. Several observational studies have examined the long-term effects 
of regular ayahuasca use in the religious context. In this work, long-term ayahuasca use has not been found to 
impact on cognitive ability, produce addiction or worsen mental health problems10,13–16. In fact, some of these 
observational studies suggest that ayahuasca use is associated with less problematic alcohol and drug use, and 
better mental health and cognitive functioning10,12,15.
However, given the apparently burgeoning use of the drug worldwide and its potential therapeutic value, 
it is important to further investigate its positive and negative effects across a wider sample of individuals and 
a broader range of users across the globe. Although observational studies assessing the long-term effects of 
ayahuasca on mental health have being conducted in Brazil, United States, and Spain, the vast majority of this 
research has been limited to religious contexts. In particular, this study using a large, self-selecting, international 
sample, sought to examine the demographics of past-year ayahuasca users and subjective effects of ayahuasca in 
people who had recently used the drug compared to other hallucinogens as a reference (the classic psychedelics, 
LSD and psilocybin). In addition, based on previous studies suggesting positive effects of ayahuasca we aimed to 
compare current well-being, past year problematic drinking and lifetime diagnoses of mental illness of past-year 
ayahuasca users and in comparison to past-year users of other hallucinogenic drugs. We then also conducted an 
exploratory analysis to assess whether there were different associations between ayahuasca use and these out-
comes in countries with and without a history of ayahuasca use. Based on previous observational research, we 
hypothesised that past-year ayahuasca users would have better well-being and less problematic drinking than 
comparison drug-using groups.
Methods
Design and participants. An international online cross-sectional drugs survey, the Global Drug Survey 
2016 (GDS), was conducted between November 2015 and February 2016. GDS recruits participants by work-
ing in partnership with global media partners (e.g. advertising via Mixmag, The Guardian and Fairfax Media) 
and onward promotion through social media. This method has previously been employed to explore the use of 
uncommon and new drugs17–19. All participants were aged 16 years of age or over, none disclosed identifying 
information online, and all provided informed consent. Before taking the survey, potential respondents were 
made aware that the information they provide is anonymous and confidential, that you can withdraw at any 
time, that the GDS is the world’s largest annual drug survey, and that there is no financial incentive but that you 
are contributing to a better understanding of drug use around the world. Ethical approval was received from the 
Psychiatry, Nursing and Midwifery Research Ethics Subcommittee at King’s College London. The survey was 
conducted in line with the research ethics committee requirements.
Assessments. The survey collected demographic data and detailed information on drug use. Respondents 
were asked about: their country of residence, gender (male, female, transgender), age, self-reported well-being, 
presence of a lifetime diagnosis of a mental illness and current problematic alcohol consumption. Self-reported 
well-being was measured using the Personal Wellbeing Index20, which has a maximum score of 80. Problematic 
alcohol use within the last year was measured using the Alcohol Use Disorder Identification Test (AUDIT)21, 
which has a maximum score of 40 and a hazardous drinking cutoff of >8. For this study, participants were asked 
about their ayahuasca use, and for comparison, their LSD and magic mushroom use (the two most commonly 
taken classic hallucinogens).
In order to compare demographic variables, current well-being, past year problematic drinking and lifetime 
mental illness we formed three groups: Ayahuasca Users (those who had taken ayahuasca in the last year), Classic 
Psychedelic Users (those who had taken either LSD or magic mushrooms in the last year, but not ayahuasca in 
the last year), and Other Respondents (those who had not taken ayahuasca, LSD or magic mushrooms in the last 
year). We combined past-year magic mushroom and past-year LSD users because these drugs are the two most 
popular serotonergic psychedelic drugs, have similar actions in the brain and we believe users of both drugs form 
a coherent group (evidence for this is reported in the results).
In addition, we stratified participants into those from countries with historical ayahuasca use and those from 
countries without historical ayahuasca. Countries considered to have a history of ayahuasca use were Bolivia, 
Brazil, Colombia, Ecuador, Peru and Venezuela. All other countries were considered not to have a history of 
ayahuasca use. We investigated whether differences between user groups (Ayahuasca, Classic Psychedelic, Other 
Respondents) existed in both countries with historical ayahuasca use and countries without historical ayahuasca 
use, or if they only existed on one type of country.
Moreover, respondents were asked to name the last new drug that they tried and answer questions about 
their subjective experience. We focused on respondents whose last new drug tried was ayahuasca, LSD or magic 
mushrooms. Specifically, they were asked to rate from 0 to 10: ‘the pleasurable high’, ‘the strength of the effect’, 
‘the negative effects while high’, ‘the comedown after use’, ‘the urge to use more of the drugs when using’, ‘the 
value-for-money’ and ‘the risk of harm following a session of use’. Therefore, we could compare the subjective 
effects of ayahuasca with LSD and magic mushrooms, in new users. We only analysed data from people who 
reported taking ayahuasca and magic mushrooms orally or people who reported taking LSD either orally or 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 15201  | DOI:10.1038/s41598-017-14700-6
sublingually. Furthermore, for ayahuasca, we report how the drug was sourced, how long the effects lasted, how 
long it took for ‘peak effects’ to occur after a single dose, and what the ‘predominant effect’ of the drug was.
Statistical analyses. Descriptive statistics are provided for the demographic variables. Where data are miss-
ing, we report valid percentages, rather than absolute percentages.
We used one-way between-group ANOVAs and chi-square tests to compare the Ayahuasca User, Classic 
Psychedelic User and Other Respondent groups on age, gender, country of residence, past year problematic alco-
hol use, current well-being and lifetime mental illness diagnosis. In addition, we employed chi-square tests and 
two-way ANOVAs to investigate whether coming from a country with or without historical ayahuasca use mod-
erated the above differences.
We used one-way between-group ANOVAs to compare the ratings of drug effects of ayahuasca, LSD and 
magic mushrooms in those whose last new drug tried was one of those.
If the groups had unequal variances then Welch’s tests (for one-way ANOVA) and t-tests allowing for unequal 
variances were used; this is reflected in the degrees of freedom reported where the second degree of freedom 
is not an integer. This was the case for all drug effect ANOVAs and many of the Ayahuasca/Psychedelic/Other 
Respondent group ANOVAs. Post-hoc t-tests and post-hoc z-tests (for proportions) were Bonferoni corrected. 
Data relevant to the results are available on request.
Data is available on request to other researchers who are interested in this manuscript.
Results
During cleaning of the data, 3,817 records were excluded due to data capture glitches, duplicate entries, reporting 
no psychoactive drug use at all (including alcohol), reporting the use of a fake drug, and being 100 years of age 
or over.
Whole sample demographics. A total of 100,711 responses were recorded. After exclusion of invalid 
responses, there were 96,901 responses remaining. The number of respondents from each country, that has at 
least 1,000 respondents, is shown in Table 1.
The majority of respondents were male (n = 62,584, 65.6%), 32,547 respondents were female (34.1%) and 449 
were transgender (0.5%). The mean age of respondents was 28.71 (SD = 11.18).
A relatively small number of respondents reported lifetime ayahuasca use (n = 1,407, 1.5%) compared to over 
a quarter of the sample reporting lifetime magic mushroom or LSD use (n = 27,146, 28.0%; n = 25,953, 26.8%, 
respectively). Within the last year, 527 people (0.5%) reported ayahuasca use.
Ayahuasca Users, Classic Psychedelic Users and Other Respondents. We split the respondents 
into: Ayahuasca Users (those who had used ayahuasca in the last year, n = 527), Classic Psychedelic Users (those 
who had used magic mushrooms and LSD, but not ayahuasca, in the last year, n = 18,138) and Other Respondents 
(other respondents who had not used any of these drugs in the last year, n = 78,236).
Drug use. Use of commonly used recreational drugs in all three groups is reported in Table 2. There was a general 
pattern for more of the Classic Psychedelic Users and Ayahuasca Users to have used recreational drugs in their life-
time and in the last month than the Other Respondents.
Country Number of respondents % of sample
Germany 29,866 30.8
Switzerland 8,174 8.4
New Zealand 7,633 7.9
U.K. 6,015 6.2
U.S.A. 5,367 6.2
Netherlands 5,058 5.2
Australia 4,931 5.1
France 3,858 4.0
Italy 3,189 3.3
Hungary 3,071 3.2
Spain 2,520 2.6
Colombia 2,095 2.2
Austria 2,055 2.1
Norway 1,461 1.5
Canada 1,297 1.3
Mexico 1,203 1.2
Belgium 1,027 1.1
Table 1. The number of respondents in the sample from different countries. Only countries with n > 1,000 are 
shown.
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Demographic variables. There was a main effect of user group on age (F2, 1377.17 = 122.24, p < 0.001). Ayahuasca 
Users (mean = 29.09, SD = 10.03, n = 515) were older than the Classic Psychedelic Users (mean = 24.17, 
SD = 6.79, n = 17,937) (t527.56 = 11.06, p < 0.001). The Ayahuasca Users had a similar age to the Other Respondents 
(mean = 29.76, SD = 11.73, n = 77,353) (t523.39 = 1.52, p = 0.26).
Fewer females than males reported ayahuasca use. Genders were not split similarly across the groups 
(χ2(4) = 928, p < 0.001). The proportion of females in the Ayahuasca User group (n = 146, 28.0%) was similar to 
the Classic Psychedelic User group (n = 4,380, 24.5%) but smaller than in Other Respondents (n = 28,021, 36.3%) 
(z = 3.92, p < 0.001).
In terms of geographical locations, some countries had more ayahuasca users (relative to the other two groups) 
than expected by chance: Argentina, Brazil, Canada, Colombia, Mexico, Portugal, Spain, Sweden, the U.K. and the 
U.S.A. The number of ayahuasca users in each country is shown in Fig. 1.
Psychological Well-Being. There was a main (Fig. 2) effect of user group on reported well-being (F2, 1372.22 = 10.70, 
p < 0.001). The Ayahuasca Users (mean = 58.17, SD = 11.98, n = 521) reported greater well-being than the Classic 
Psychedelic Users (mean = 55.92, SD = 11.91, n = 17,893) (t550.364 = 4.217, p < 0.001) and the Other Respondents 
(mean = 55.88, SD = 12.07, n = 77,473) (t527.124 = 4.329, p < 0.001).
Past Year Problematic Alcohol Use. There was a main effect of user group on total AUDIT score (F2, 
1777.96 = 692.36, p < 0.001). The Ayahuasca User group (mean = 9.41, SD = 5.91, n = 458) had a lower total AUDIT 
score than the Classic Psychedelic User group (mean = 10.33, SD = 5.94, n = 16,615) (t17071 = 3.216, p = 0.002). 
However, the Ayahuasca User group had a higher total AUDIT score than the Other Respondents (mean = 8.45, 
SD = 5.50, n = 68,775) (t69231 = 3.73, p < 0.001). Importantly, all three groups would meet the hazardous drinking 
criterion of >8.
Lifetime Mental Illness Diagnoses. The proportion of people who reported having a diagnosed mental illness 
in their lifetime was not similar across the groups (χ2(2) = 133.36, p < 0.001). There was a similar proportion of 
people who reported having ever been diagnosed with a mental illness in the Ayahuasca User group (n = 129, 
24.9%) and the Classic Psychedelic User group (n = 4,014, 22.4%), but a larger proportion in the Ayahuasca User 
group compared with the Other Respondents (n = 14,549, 18.8%) (z = 5.48, p < 0.001).
Drug
% Ever used (n) % Used in last month (n)
Other 
Respondents
Classic 
Psychedelic Ayahuasca
Other 
Respondents
Classic 
Psychedelic Ayahuasca
Alcohol 97.9% (76,611) 98.5% (17,874) 97.5% (514) 86.5% (67,663) 90.4% (16,396) 87.1% (459)
Cannabis 76.7% (59,981) 97.6% (17,696) 94.9% (500) 41.3% (32,286) 83.3% (15,107) 78.7% (415)
Tobacco 75.1% (58,793) 84.4% (15,305) 79.5% (419) 48.5% (37,983) 67.1% (12,165) 59.8% (315)
Ecstasy/MDMA 34.3% (26,822) 80.9% (14,682) 71.5% (377) 10.0% (7,862) 38.4% (6,967) 24.7% (130)
Cocaine 27.5% (21,531) 58.5% (10,607) 61.5% (324) 7.3% (5,732) 22.7% (4,120) 17.6% (93)
Amphetamine 20.4% (15,975) 46.1% (8,358) 37.4% (197) 4.7% (3,662) 17.8% (3,233) 8.9% (47)
Magic Mushrooms 16.9% (13,204) 74.9% (13,539) 66% (348) 0% (0) 13.4% (2,434) 13.1% (69)
LSD 14.8% (11,584) 76.9% (13,953) 78.7% (415) 0% (0) 21.4% (3,879) 21.6% (114)
Methamphetamine 4.1% (3,179) 9.5% (1,725) 11.2% (59) 0.5% (410) 1.8% (321) 0.9% (5)
Heroin 3.0% (2,308) 5.3% (953) 7.2% (38) 0.4% (310) 1.1% (197) 0.8% (4)
Ayahuasca 0.5% (419) 2.5% (461) 100% (527) 0% (0) 0% (0) 18.2% (96)
Table 2. The percentages and numbers of lifetime and last month drug use within Other Respondents (total 
n = 78,236), Classic Psychedelic Users (total n = 18,138) and Ayahuasca Users (total n = 527).
Figure 1. The number of ayahuasca users (people who have taken ayahuasca in the last year) in different 
countries. *Designates countries where there were more ayahuasca users than expected by chance, relative to 
classic psychedelic users and other respondents. Only countries with n ≥ 5 ayahuasca users are shown.
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Differences within Classic Psychedelic Users. We grouped magic mushroom and LSD users together as a com-
parison group. Evidence that respondents who used LSD in the last year but did not use magic mushrooms in the 
last year are similar to those who used magic mushrooms in the last year but did not use LSD in the last year is as 
follows: these groups did not differ on age (p = 0.270), wellbeing (p = 0.699), problematic drinking (p = 0.319) 
and gender (p = 0.962). However, the only last-year LSD users were slightly more likely to have a lifetime mental 
illness diagnosis than the only last-year magic mushroom users (χ2(1) = 5.113, p = 0.024).
Exploratory analysis of countries with and without a history of ayahuasca use. Given our find-
ings above, we explored whether being from a country with a history of ayahuasca use moderated the relationship 
between ayahuasca use and various outcomes.
Psychological Well-being. There was an interaction between User Group and Country Type on well-being (F2, 
690.98 = 4.77, p = 0.009). Post-hoc t-tests showed that, within the countries with a history of ayahuasca use, there 
were no differences in psychological wellbeing between the user groups. However, within the countries with-
out a history of ayahuasca use, Ayahuasca Users had a higher well-being (mean = 58.66, SD = 11.95, n = 406) 
than Classic Psychedelic Users (mean = 55.91, SD = 11.87, n = 16,723) (t2.74, p < 0.001) and Other Respondents 
(mean = 55.86, SD = 12.06, n = 77,460) (t2.80, p < 0.001).
Lifetime Mental Illness Diagnoses. We found that amongst countries with a history of ayahuasca use there were 
no differences in incidence of lifetime mental illness diagnoses between Ayahuasca Users, Classic Psychedelic 
Users and Other Respondents. However in countries without a history of ayahuasca use there was a significant 
difference between incidence of lifetime mental illness diagnoses (χ2 (1) = 168.05, p < 0.001). Ayahuasca Users 
had a significantly greater history of mental illness diagnoses (n = 114, 28.3%) than Classic Psychedelic Users 
(n = 3,849, 23%) who in turn had a significantly greater lifetime incidence than Other Respondents (n = 14,262, 
18.9%).
Past Year Problematic Use. There was no interaction between User Group and Country Type for AUDIT scores.
For those who said ayahuasca was their most recently tried new drug. 192 people said ayahuasca 
was the drug they had most recently tried for the first time. Of these, 191 reported their route of administration: 
166 people (86.9%) swallowed it, 20 people (10.5%) said ‘other’, which equated to ‘swallowed’ (e.g. ‘drank it’), and 
5 people (2.6%) said they smoked it. As stated above, only respondents who reported taking ayahuasca orally (i.e. 
‘swallow’ or ‘other’) were included in these analyses. As smoking ayahuasca is not a viable route of administration, 
these respondents were excluded in these analyses.
50 people (26.9%) had sourced the ayahuasca from a friend, 13 (7.0%) from a website, 5 (2.7%) from a family 
member, 3 (1.6%) from a dealer, 1 (0.5%) from a headshop and 114 (61.3%) from ‘other’. Of those who said ‘other’, 
there were a variety of responses, but apart from 3 (‘Holland’, ‘Organisation’, ‘Self-Brewed’), these all referred, in 
essence, to a ‘shaman’ or a ‘healer’. Examples include: ‘Healing centre’, ‘At Retreat’, ‘Ceremony’, ‘Church’, ‘Santo 
Daime’, ‘Teacher’, ‘Trained Facilitator’.
51 people (27.4%) said they had already taken it again since the first time; 86 people (46.2%) said they planned 
to take it again but had not yet; and 15 people (8.1%) said they did not plan to take it again.
Duration of effect. The median and modal reported duration of effect was 6 hours (n = 40) (see Fig. 3), 
although there was some positive skew with 4 people reporting a duration of effect of 24+ hours.
Time to peak effect. The median and modal estimated time to peak effect was 1 hour (n = 34) (see Fig. 4).
Subjective effects. Most people (n = 131, 70.8%) described ayahuasca as ‘mostly psychedelic’, three peo-
ple (1.6%) described it as ‘mostly cannabis like’, two people (1.1%) described it as ‘mostly empathogen like’, one 
person described it as ‘mostly stimulant like’ and 48 people (25.9%) stated ‘other’. Of those that said ‘other’, most 
Figure 2. Bar chart of self-reported well-being on the Personal Wellbeing Index20, which has a maximum score of 
80. Bars show mean scores. Error bars show standard error scores.
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described it as (or something similar to): ‘spiritual’, ‘medicine’, ‘healing’, ‘hallucinogenic’, ‘indescribable’. Two peo-
ple reported ‘feeling nothing’. Other responses (of n = 1) included: ‘crazy’, ‘nausea’, ‘introspective’.
Ratings of the effects of ayahuasca/LSD/magic mushrooms were reported by people whose last new drug they 
had tried was ayahuasca/LSD/magic mushrooms, respectively (see Table 3). The strength of effect of ayahuasca 
was rated as greater than LSD (t189.22 = 189.22, p = 0.014) and magic mushrooms (t196.51 = 7.94, p < 0.001). The 
pleasurable effects of ayahuasca were rated as smaller than LSD (t184.337 = 2.66, p = 0.018). The negative effects 
while high on ayahausca were rated as greater than LSD (t184.07 = 3.382, p = 0.002) and Magic Mushrooms 
Figure 3. The number of people who reported ayahuasca’s duration of effect, from 0.25 hours to 24+ hours 
(n = 181). Only people whose last new drug tried was ayahuasca answered this question.
Figure 4. The number of people who reported ayahuasca’s time to peak effect, from 10 mins to 6+ hours 
(n = 179). Only people whose last new drug tried was ayahuasca answered this question.
Ayahuasca LSD Magic Mushrooms F (df1, df2)
The pleasurable high 7.15 (2.82), n = 178
7.72 (2.13), 
n = 4944
7.14 (2.27), 
n = 3844
76.22 (2, 
472.11)***
Strength of effect 8.26 (2.19), n = 179
7.80 (2.03), 
n = 4935
6.92 (2.29), 
n = 3828
187.88 (2, 
481.22)***
Negative effects when high 3.88 (3.15), n = 176
3.07 (2.64), 
n = 4842
2.72 (2.66), 
n = 3741
26.480 (2, 
469.47)***
Comedown after use 2.15 (2.65), n = 177
3.49 (2.83), 
n = 4837
2.63 (2.54), 
n = 3744
117.86 (2, 
478.70)***
Urge to use more when 
intoxicated
0.8 (1.71), 
n = 178
1.39 (2.23), 
n = 4878
1.41 (2.24), 
n = 3790
10.60 (2, 
493.32)***
Value-for-money 7.57 (2.90), n = 176
7.79 (2.46), 
n = 4819
7.26 (2.69), 
n = 3718
44.19 (2, 
470.18)***
Risk of harm following a 
session of use
1.44 (1.96), 
n = 179
2.72 (2.72), 
n = 4888
2.19 (2.41), 
n = 3800
69.63 (2, 
497.14)***
Table 3. Drug effect profiles of ayahuasca, LSD and magic mushrooms, among subsamples who reported 
recently trying these drugs for the first time. Mean (SD). Ns vary slightly for each drug effect rating due to missing 
data. ***p < 0.001. Welch’s ANOVAs were used due to a violation of the homogeneity of variance assumption.
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(t186.87 = 4.82, p < 0.001). The comedown after ayahuasca was rated as smaller than LSD (t191.04 = 6.60, p < 0.001) 
and Magic Mushrooms (t191.68 = 2.39, p = 0.034). The urge to use more of ayahuasca was rated as smaller than LSD 
(t199.52 = 4.46, p < 0.001) and Magic Mushrooms (t206.58 = 4.56, p < 0.001). The risk of harm following a session of 
ayahuasca was rated as lower than LSD (t204.05 = 8.49, p < 0.001) and magic mushrooms (t204.31 = 4.98, p < 0.001). 
Finally, there were no significant differences between ratings of value for money between Ayahuasca and the other 
drugs.
Discussion
This study aimed to investigate the characteristics of past-year ayahuasca users (who will be referred to simply 
as ‘ayahuasca users’), their current well-being, their past year problematic alcohol use and their lifetime mental 
illness diagnoses relative to comparison drug user groups, and the subjective effects of ayahuasca in new users. 
Given prior observational research with individuals taking the drug in a religious context, we hypothesised that 
ayahuasca users would have better current well-being and less past year problematic drinking.
In the current study, ayahuasca users reported greater well-being than past-year LSD and magic mushroom 
users (who will be referred to simply as ‘classic psychedelic users’) and the non-psychedelic using other respond-
ents. Ayahuasca users reported less problematic drinking than classic psychedelic drug users. However, both 
groups would be considered hazardous drinkers according to the AUDIT cut-off and both groups reported higher 
greater problematic drinking than the other respondents in this survey. Ayahuasca and classic psychedelic users 
were also more likely to report lifetime diagnoses of mental health problems than other survey respondents.
We also examined the subjective effects of ayahuasca in people whose most recently taken new drug was 
ayahuasca. The modal and median duration of effect of ayahuasca was 6 hours and the modal and median time 
to peak effect was 1 hour. Generally, compared to LSD and magic mushrooms, ayahuasca was rated as: stronger; 
less pleasurable; having more negative effects while high; having weaker ‘comedown’ effects after use; creating less 
of an urge to use more; and having less risk of harm following a session of use. Ayahuasca users were more likely 
to live in countries in South America, particularly Colombia (n = 66) and Brazil (n = 46). The vast majority of 
new ayahuasca users ingested the drug via swallowing or drinking, and most acquired the drug from a shaman 
or a ‘healer’. Across the whole survey, ayahuasca use was also substantially less common than use of LSD or magic 
mushrooms. However, it is important to note that the survey was self-selecting and so these values do not reflect 
true estimates of the proportions of people worldwide who use these drugs.
Self-rated psychological well-being was better in ayahuasca users than either classic psychedelic users or other 
respondents in the survey. This finding fits with previous studies that have found beneficial effects of ayahuasca 
use on subjective well-being13,22. It is of particular interest that ayahuasca users had better well-being than classic 
psychedelic users. DMT (the main active compound in ayahuasca), LSD and psilocybin (the active compound in 
magic mushrooms) all cause their psychedelic effects primarily via agonism of the 5-HT2A receptor23,24. Therefore, 
some other pharmacological difference, perhaps due to the non-DMT compounds in ayahuasca; a difference in 
the way the drugs are taken; or a pre-existing difference in the kinds of people who use ayahuasca compared with 
LSD and magic mushrooms, may explain this finding. The ceremonial nature of ayahuasca consumption, and the 
supporting community, may contribute to its positive effects on well-being. Interestingly, these data do not rep-
licate findings that the use of classic psychedelic drugs is associated with greater well-being in the long-term25,26, 
as this effect was not observed in the classic psychedelic users compared to other respondents. This may well be 
a result of confounding factors, such as additional drug use and pre-existing differences between classic psyche-
delic drug users and the other respondents in this survey. Furthermore, in Griffith et al.’s studies, participants 
are usually hallucinogen-naïve, often report regular participation in religious or spiritual activities, are screened 
for mental health problems, are prepared before drug administration, are followed during and after drug effects, 
and the drug is administered in a controlled, laboratory environment under comfortable, supportive conditions. 
These characteristics may reduce adverse reactions, and are usually not present in uncontrolled settings.
This study also found a higher incidence of lifetime mental health problems in both ayahuasca users and clas-
sic psychedelic users, compared to the non-psychedelic other respondents. A previous study of ayahuasca users 
from Brazil, who were using the drug in a religious context, found lower self-rated psychopathology maintained 
over one year compared to non-drug using controls13. A limitation of our study was that current mental health 
diagnoses or psychopathology was not measured, so we cannot distinguish between rates of current or resolved 
mental health conditions. It may be that people who use more drugs, more frequently (i.e. the ayahuasca and clas-
sic psychedelic user groups engaging in poly-drug use) are likely to have more lifetime mental illness diagnoses 
than those who use less drugs, less frequently (i.e. the other respondents), unrelated to ayahuasca consumption. 
This could be a result of mental illness preceding poly-drug use, or a result of poly-drug use preceding mental 
illness diagnosis. An alternative explanation for this relationship may be that people who have or have had mental 
health problems may be trying or have tried ayahuasca and/or other psychedelic drugs as an unconventional 
treatment.
When we stratified by country of origin (with or without historical ayahuasca use), we found that life-
time mental health diagnoses were no different amongst users from countries with a history of ayahuasca use. 
Contrastingly, in those countries without traditional or religious ayahuasca use, people who used ayahuasca had 
a higher incidence of lifetime mental health diagnoses than either classic psychedelic users or other drug users. 
We might speculate that different kinds of people may be attracted to ayahuasca for different reasons in countries 
with and without historical ayahuasca use. For instance, in countries where ayahuasca has been historically used 
and is more socially accepted today, the experience may be considered more normal and therefore appeal to the 
mainstream. In contrast, in countries in which it is illegal to possess, use must be clandestine and confined to cer-
tain sub-cultures. People who engage in such illicit behaviours are more likely to have lifetime mental health diag-
noses, which may contribute to our finding. Previous work has examined the impact of cultural context on the 
response to drugs and expectation of their positive and negative effects27. The expectation of negative effects from 
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a drug is likely greater in a country where narratives of psychedelic experiences as therapeutic are largely absent28; 
this could in turn drive more negative psychedelic experiences and possibly contribute to mental health problems.
Ayahuasca has recently emerged as a promising treatment for depression29, and longitudinal studies of users 
have found lower incidence of mental health issues associated with use of the drug13. In countries without a his-
tory of ayahuasca use, we found a higher incidence of lifetime mental illness diagnoses in the ayahuasca users 
compared with the classical psychedelic users and other respondents. However, we did not measure current men-
tal health issues and so we cannot know whether ayahuasca use is associated with more or fewer current mental 
health problems. Future research should establish the direction of causality, i.e. are those with mental health prob-
lems drawn to seek out ayahuasca as a potential treatment? This explanation is congruent with the majority of the 
participants in this study reporting taking the substance in a healing context, from a shaman or other spiritual 
healer. If this were the case, it would not be incompatible with our finding of higher current ratings of well-being 
in the ayahuasca using group, relative to the other groups. However, future longitudinal studies are required to 
fully address this question.
Problematic drinking, as measured by the AUDIT, was less prevalent in ayahuasca users than the group using 
classic psychedelics. This is an interesting finding, as classic psychedelic users were similar to ayahuasca users in 
many other respects, and is concordant with previous observations of a reduction in substance use with regular aya-
huasca use30. However, ayahuasca users did show greater problematic drinking than non-psychedelic using respond-
ents in the sample. Moreover, although the groups were statistically different on this variable, the mean differences 
were relatively small. Whilst in this study it was necessary for us to compare our ayahuasca users to this broad 
and heterogenous sample of drug users, future work should aim to match more closely a comparison group. There 
were differences in drug use across these samples, such that the ayahuasca and classic psychedelic users consumed 
more substances in the previous year than the other respondents did. Therefore, given people who take ayahuasca 
are, on average, more likely to use many different drugs than the other respondents (as shown in Table 2), it is per-
haps unsurprising that they have higher problematic drinking levels. Since ayahuasca appears to have anti-addictive 
potentials, which appear to be especially significant for alcohol30, this result could alternatively suggest that users 
could be seeking ayahuasca to treat their alcohol-related problems, but it is not possible to explore these interpre-
tations due to our cross-sectional design. In order to examine the effects of ayahuasca use on alcohol use disorders 
more carefully, large longitudinal surveys and randomised controlled trials must be employed.
Ayahuasca produced a low urge to use the substance again, which is in agreement with previous findings10. In 
comparison to the classic psychedelics, themselves of a low-abuse potential31, ayahuasca engendered less desire 
to take more of the drug. These findings suggest that ayahuasca has a very low abuse potential, which speaks 
to its safety as an emerging treatment for depression, anxiety and drug addiction. Ayahuasca was rated as hav-
ing stronger negative effects while high than LSD or magic mushrooms, and these differences were the largest 
observed. This may well be related to the well-known vomit-inducing effects it has. Interestingly, ayahuasca was 
rated as being stronger, but also less pleasurable. One might speculate that the ayahuasca experience is cultivated 
to be less about ‘pleasure’ and more about meaning, spirituality and learning, than LSD and magic mushrooms, 
which are frequently taken in a recreational way.
Strengths and Limitations. One important strength of this study was the use of an international sample of 
drug users, making this the largest characterisation of ayahuasca use to date, and in the most demographically broad 
sample. This study, unlike previous work, was not confined to individuals who take the drug alongside membership 
of a syncretic church, and therefore did not confound the effects of the drug with the non-specific effects of being 
part of a specific religious organisation. Most importantly, our survey was self-selecting and so was not represent-
ative of the global population or the drug-using global population. Therefore, the conclusions we draw may not 
extend to all ayahuasca and classic psychedelic (LSD and magic mushroom) users. Moreover, we were reliant on 
self-report data and are unable to confirm the substance ingested was indeed ayahuasca, although the relatively large 
agreement in the profile of effects would suggest this was the case. It would have been useful to have data on number 
of lifetime ayahuasca sessions; we would then have been able to explore associations between extent of ayahuasca use 
and our outcomes. However, because the Global Drug Survey has a very large number of questions, questions about 
lifetime drug use were sacrificed in order to not overburden the respondents. Another limitation of the current study 
was that mental illness diagnoses were only measured over the lifetime, so it was not possible to discern current from 
resolved mental health problems. Future studies should therefore measure this variable.
Conclusions
Ayahuasca users in this international mostly took the drug with a healer or a shaman. Ayahuasca was rated as 
less pleasant and with less of an urge to use more of it than classic psychedelics. We found evidence of greater 
well-being and less problematic alcohol use in ayahuasca users compared to classic psychedelic users. However, 
the ayahuasca users did have greater problematic drinking than the non-psychedelic using respondents. There 
was a higher incidence of lifetime mental illness diagnoses within the ayahuasca users, which subsequent analyses 
found to be confined to users from countries without a tradition of ayahuasca use. There is a clear need for more 
research into the relationships between ayahuasca use, mental health, well-being and problematic alcohol and 
substance use, within this heterogeneous group of users. Nevertheless, our findings of increased well-being and 
less problematic alcohol use amongst ayahuasca users, compared to their classic psychedelic using counterparts, 
lends limited support to the notion that ayahuasca may prove to be an important and powerful adjunct for the 
treatment of depression and alcohol use disorders. Well controlled studies of ayahuasca must be therefore be 
conducted in order to rigorously test its safety and efficacy within psychiatric disorders.
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